
Balaji Amines Q4 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- The company conservatively forecasts revenue of Rs. 2,500 crores for the next year, factoring in potential price declines although EBITDA and EPS are expected to remain stable. (Page 15)
- Full capacity utilization of existing and new plants (N-Butyl Amine, Acetonitrile, Methylamine, DMF) is expected by end of FY25, targeting a revenue of around Rs. 4,000 crores. (Page 14)
- FY23 standalone revenue is guided between Rs. 2,200 to Rs. 2,300 crores; consolidated revenue should reach Rs. 2,500 crores. (Page 12)
- Subsidiary's turnover expected to grow to Rs. 700-750 crores in FY23, with capacity utilization rising to 70%-80%. (Page 4)
- Volumes are anticipated to grow annually by approximately 10%-15%, with total volumes projected to exceed 1,15,000 metric tons. (Page 8)
- New products like DMC and Propylene Glycol expected to add Rs. 300 crores in revenue once fully operational. (Page 9)
- Export revenue share aimed to increase to 30%-35% of total revenues to mitigate risks related to imported raw materials. (Page 9)
See what Balaji Amines management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- Majority of the planned CAPEX will be funded through internal accruals.
- A few crores of borrowing might be considered toward the end of the completion phase if required.
- There is a credit committee in the subsidiary board evaluating options including possible mergers, but no specific mention of fresh equity fundraising.
- No explicit plans for equity fundraising were disclosed in the provided transcript.
- Overall, the company appears focused on utilizing internal funds with limited external borrowing potential for near-term investments.
See what Balaji Amines management said on order book — free account, 30 seconds.
Capex plans
Yes- Phase-2 Greenfield project CAPEX planned for FY23 and FY24 is Rs. 300 to 400 crores.
- Four new plants being installed under this phase:
- - N-Butylamine plant with 15,000 tons capacity.
- - Acetonitrile plant with 15,000 tons capacity.
- - Methylamine plant with 40,000 tons capacity.
- - DMF plant with 30,000 tons capacity.
- Production at these plants expected to commence between mid FY24 and end of FY25.
- Majority of the CAPEX funding will be from internal accruals; minor borrowing possible towards project completion.
- Plans to expand and diversify the product portfolio with new products like DMC and propylene glycol.
- The company is also evaluating debottlenecking and potential derivatives addition at subsidiaries to grow capacity further.
Track Balaji Amines — get its next earnings analysis in your feed
How does Balaji Amines rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Balaji Amines rank in Chemicals & Petrochemicals?
Compare Balaji Amines against every Chemicals & Petrochemicals company (Q4 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Balaji Amines's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…